A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and multiple myeloma have poor outcomes. CAR-T completely changed the landscape of therapy options, improving not only response rates but also survival outcomes. Hematological toxicity after chimeric...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1465802/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846164575419891712 |
|---|---|
| author | Vadim Lesan Konstantinos Christofyllakis Moritz Bewarder Lorenz Thurner Jörg Bittenbring |
| author_facet | Vadim Lesan Konstantinos Christofyllakis Moritz Bewarder Lorenz Thurner Jörg Bittenbring |
| author_sort | Vadim Lesan |
| collection | DOAJ |
| description | Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and multiple myeloma have poor outcomes. CAR-T completely changed the landscape of therapy options, improving not only response rates but also survival outcomes. Hematological toxicity after chimeric antigen receptor therapy (CAR-T) is of increasing interest, being a recognized prognostic factor in this setting. We report our experience with early hematological toxicity after CAR-T therapy and point some important aspects regarding the Hematotox-Score. We identified a strong negative correlation between Hematotox-Score and platelet count at first day of cytokine release syndrome (CRS). Hematotox-Score was predictive of hemoglobin levels at day 28 after CAR-T. Ferritin remained high after 28 days post CAR-T in patients with high Hematotox-Score. Hematotox-Score did not associate with mortality in our cohort. We did not find any significant association between the hematological parameters (hemoglobin, platelets, and neutrophil counts), ferritin, LDH at first day of CRS and mortality. In conclusion, we demonstrate that Hematotox-Score is predictive of early hematological toxicity after CAR-T. Although, patients with higher degree of hematological toxicities have poorer survival outcomes, Hematotox-Score lacks predictive potential, probably due to its limitations. Further development of hematological scores predicting survival outcome in the context of CAR-T are needed. |
| format | Article |
| id | doaj-art-cfc9d0c2a621425da4969c26d5253997 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-cfc9d0c2a621425da4969c26d52539972024-11-18T04:22:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-11-011110.3389/fmed.2024.14658021465802A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicityVadim LesanKonstantinos ChristofyllakisMoritz BewarderLorenz ThurnerJörg BittenbringPatients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and multiple myeloma have poor outcomes. CAR-T completely changed the landscape of therapy options, improving not only response rates but also survival outcomes. Hematological toxicity after chimeric antigen receptor therapy (CAR-T) is of increasing interest, being a recognized prognostic factor in this setting. We report our experience with early hematological toxicity after CAR-T therapy and point some important aspects regarding the Hematotox-Score. We identified a strong negative correlation between Hematotox-Score and platelet count at first day of cytokine release syndrome (CRS). Hematotox-Score was predictive of hemoglobin levels at day 28 after CAR-T. Ferritin remained high after 28 days post CAR-T in patients with high Hematotox-Score. Hematotox-Score did not associate with mortality in our cohort. We did not find any significant association between the hematological parameters (hemoglobin, platelets, and neutrophil counts), ferritin, LDH at first day of CRS and mortality. In conclusion, we demonstrate that Hematotox-Score is predictive of early hematological toxicity after CAR-T. Although, patients with higher degree of hematological toxicities have poorer survival outcomes, Hematotox-Score lacks predictive potential, probably due to its limitations. Further development of hematological scores predicting survival outcome in the context of CAR-T are needed.https://www.frontiersin.org/articles/10.3389/fmed.2024.1465802/fulllymphomaCAR-Thematological toxicityHematotox-Scoreearly toxicity |
| spellingShingle | Vadim Lesan Konstantinos Christofyllakis Moritz Bewarder Lorenz Thurner Jörg Bittenbring A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity Frontiers in Medicine lymphoma CAR-T hematological toxicity Hematotox-Score early toxicity |
| title | A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity |
| title_full | A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity |
| title_fullStr | A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity |
| title_full_unstemmed | A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity |
| title_short | A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity |
| title_sort | single center retrospective study on real world car t cell therapy focus on early hematological toxicity |
| topic | lymphoma CAR-T hematological toxicity Hematotox-Score early toxicity |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1465802/full |
| work_keys_str_mv | AT vadimlesan asinglecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT konstantinoschristofyllakis asinglecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT moritzbewarder asinglecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT lorenzthurner asinglecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT jorgbittenbring asinglecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT vadimlesan singlecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT konstantinoschristofyllakis singlecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT moritzbewarder singlecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT lorenzthurner singlecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity AT jorgbittenbring singlecenterretrospectivestudyonrealworldcartcelltherapyfocusonearlyhematologicaltoxicity |